Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease

In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, 2017-002971-24.).

Publication Details

Journal: New England Journal of Medicine
Published: 2024-10-25
DOI: https://doi.org/10.1056/nejmoa2409183
Citations: 80
Primary Topic: Diabetes Treatment and Management
Type: article
Field-Weighted Citation Impact: 28.26

Funders

Boehringer Ingelheim
Eli Lilly and Company
British Heart Foundation
Medical Research Council
NIHR Oxford Biomedical Research Centre

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease

Oct 25, 2024

80 citations

New England Journal of Medicine

Diabetes Treatment and Management

28.26

article

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease

October 25, 2024article en

80 citations

Abstract

New England Journal of MedicineVol. 392(8)

Boehringer Ingelheim, Eli Lilly and Company, British Heart Foundation, Medical Research Council, NIHR Oxford Biomedical Research Centre

Good health and well-being

Openalex Percentile: Top 0%

Diabetes Treatment and Management

28.26

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.